Free Trial

Exicure Q3 2023 Earnings Report

Exicure logo
$14.28 +2.96 (+26.15%)
As of 04:00 PM Eastern

Exicure EPS Results

Actual EPS
-$0.61
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Exicure Earnings Headlines

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
Exicure announces purchase agreement with GPCR Therapeutics
“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
Exicure signs MOU with GPCR Therapeutics
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat